ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Will Try Camurus’s FluidCrystal D
ScripIt has been a good week for Bayer’s oncology franchise, securing a third indication for its prostate cancer blockbuster Nubeqa and presenting positive data on its investigational menopause drug elinza
In VivoAs major pharmaceutical companies continue investing heavily in immunology –with Sanofi’s recent $9.1bn acquisition of Blueprint Medicines underscoring the sector’s strategic importance – San Franci
ScripBayer’s hopes of catching up with Boehringer Ingelheim’s small molecule HER2 inhibitor zongertinib have been boosted by regulators in the US putting sevabertinib, its same-class candidate for lung can